NASDAQ:PLUR Pluri Q2 2026 Earnings Report $1.36 -0.01 (-0.73%) As of 03:58 PM Eastern ProfileEarnings HistoryForecast Pluri EPS ResultsActual EPS-$0.71Consensus EPS -$0.65Beat/MissMissed by -$0.06One Year Ago EPSN/APluri Revenue ResultsActual Revenue$0.20 millionExpected Revenue$0.64 millionBeat/MissMissed by -$440.00 thousandYoY Revenue GrowthN/APluri Announcement DetailsQuarterQ2 2026Date2/12/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsPluri's next earnings date is estimated for Wednesday, September 23, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pluri Earnings HeadlinesPluri Announces August 2026 Equity Financing TransactionAugust 28, 2026 | tipranks.comPluri prices $3.3 million offeringAugust 27, 2026 | seekingalpha.comTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the entire proven US reserve of 46 billion barrels. The deal includes a 35% government stake, guaranteed oil access, and century-long concessions, while pushing Chinese operators out of the region entirely. One analyst believes this is about more than oil. It could be the opening move in a dollar reset that hasn't happened since 1974.September 4 at 1:00 AM | Porter & Company (Ad)Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional InvestorAugust 27, 2026 | globenewswire.comPluri Subsidiary Acquires Fishway to Expand Cultivated SeafoodAugust 17, 2026 | tipranks.comPluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic InvestmentAugust 17, 2026 | globenewswire.comSee More Pluri Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email. Email Address About PluriPluri (NASDAQ:PLUR) (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting. Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies. Its PLX cell therapies have been evaluated in clinical studies targeting critical limb ischemia, hematopoietic support following radiation exposure and tissue repair in musculoskeletal injuries. The company has also received grant funding for programs addressing acute radiation syndrome and continues to explore additional indications in immune and inflammatory diseases. Headquartered in Haifa, Israel, Pluri operates a GMP-certified manufacturing facility capable of supporting commercial-scale production. The company’s global footprint extends to clinical trial sites and partnership agreements in the United States, Europe and the Asia-Pacific region. Pluri’s leadership team brings extensive expertise in regenerative medicine, cellular manufacturing and regulatory affairs as it works toward potential market authorization and broad clinical adoption of its cell therapy products.View Pluri ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
